1244772-79-9Relevant academic research and scientific papers
A novel series of [3.2.1] azabicyclic biaryl ethers as α3β4 and α6/4β4 nicotinic receptor agonists
Lowe III, John A.,Deninno, Shari L.,Coe, Jotham W.,Zhang, Lei,Mente, Scot,Hurst, Raymond S.,Mather, Robert J.,Ward, Karen M.,Shrikhande, Alka,Rollema, Hans,Johnson, David E.,Horner, Weldon,Gorczyca, Roxanne,Tingley III, F. David,Kozak, Rouba,Majchrzak, Mark J.,Tritto, Theresa,Sadlier, Jen,Shaffer, Chris L.,Ellerbrock, Brenda,Osgood, Sarah M.,MacDougall, Mary C.,McDowell, Laura L.
supporting information; experimental part, p. 4749 - 4752 (2010/10/04)
We report the synthesis of a series of [3.2.1]azabicyclic biaryl ethers as selective agonists of α3- and α6-containing nicotinic receptors. In particular, compound 17a from this series is a potent α3β4 and α6/4β4 receptor agonist in terms of both binding and functional activity. Compound 17a also shows potent in vivo activity in CNS-mediated animal models that are sensitive to antipsychotic drugs. Compound 17a may thus be a useful tool for studying the role of α3β4 and α6/4β4 nicotinic receptors in CNS pharmacology.
